Business Wire

AL-ADTRAN

24.6.2024 14:01:33 CEST | Business Wire | Press release

Share
Adtran and Iridium strengthen PNT resilience in Europe and Asia-Pacific with Satellite Time and Location technology

Adtran, in partnership with Iridium Communications Inc. (NASDAQ: IRDM), today announced the European and Asia-Pacific launch of its synchronization solutions featuring Iridium® Satellite Time and Location (STL) technology, a significant step in countering growing threats to Global Navigation Satellite Systems (GNSS). Adtran’s OSA 5405-S PTP compact grandmaster clock with STL capabilities and its OSA 5400 STL module are now available to timing network operators in Western Europe, major countries in Eastern Europe, Turkey, and parts of Asia-Pacific, including the majority of Southeast Asia, Japan and South Korea. The solutions enhance the resilience and reliability of critical infrastructure, such as 5G networks, defense systems and many more. Leveraging low-Earth orbit (LEO) satellites to deliver precise and secure positioning, navigation and timing (PNT) services, the devices ensure continuous synchronization even in environments where GNSS is compromised. As a certified Iridium partner, Adtran offers the technology through two distinct purchasing options: an annual service license for optimal flexibility or bundled with equipment for long-term financial planning.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624939927/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adtran’s synchronization solution featuring Iridium® STL services will bring new levels of PNT security to Europe and Asia-Pacific. (Photo: Business Wire)

“The weakness of GNSS signals is increasingly being exploited to create serious problems. As Europe, APAC and the rest of the world have become more dependent on PNT data, attacks on GNSS have only escalated, creating an urgent need to pivot away from the exclusive use of these satellites,” said Michael O’Connor, executive vice president of PNT at Iridium. “By integrating our STL service into Adtran Oscilloquartz devices and making it available across much of Europe and key areas of APAC, we’re providing network operators with valuable new options. They can choose to use our solution as a primary source of timing data in indoor environments, or they can leverage our secure, high-strength LEO signals as a backup source of PNT information when GNSS is unavailable. This offers the strongest ever safeguard against the threats that compromise so many aspects of our daily lives.”

Iridium® STL services harness the power of LEO satellites to transmit encrypted signals that are 1,000 times stronger than those of GNSS, significantly reducing vulnerability to disruptions and manipulation. The technology excels in challenging environments like urban canyons and indoor areas and can penetrate deep into buildings without the need for rooftop antennas. STL services are now a key feature of Adtran’s Oscilloquartz product lineup. The versatile OSA 5405-S PTP grandmaster clock supports STL time services and multi-constellation GNSS, as well as various other timing sources, all within a zero-trust architecture that leverages multiple diverse timing sources for enhanced resilience. Additionally, the OSA 5400 STL module extends these advanced STL/GNSS receiver capabilities to third-party equipment requiring timing, enabling precise, robust synchronization for a wide range of applications.

“We partnered with Iridium to bring the benefits of its STL services to critical timing infrastructure around the world because we share a common goal. We’re committed to making PNT networks as resilient and secure as possible. STL is a powerful solution for fortifying zero-trust architecture and ensuring reliable PNT even when GPS signals fail, making it ideal for both indoor and challenging outdoor locations. By empowering operators of mission-critical networks to access reliable timing in the most demanding environments, we’re also eliminating the need to install outdoor antennas and core through concrete, significantly reducing expenses,” commented Gil Biran, GM of Oscilloquartz, Adtran. “We’re excited to bring these advantages to so many more customers across Europe and APAC. Today’s announcement marks a significant advancement for the network operators and people of these regions, whose daily lives increasingly depend on robust PNT.”

Adtran is making STL services readily available in ways that perfectly align with the evolving needs of modern network infrastructures, offering two purchasing models designed to maximize operational flexibility and support financial planning. The ‘opex model’ provides an annual service license, which is ideal for operators that need adaptable yearly budgeting. Conversely, the ‘capex model’ bundles STL services with essential equipment for 3, 5 or 10 years, facilitating cost amortization similar to traditional GNSS systems. These options make the benefits of LEO satellite signals – whether as a robust primary timing source or a highly reliable backup to GNSS – accessible to sectors where reliable and secure PNT is paramount, including 5G, data centers, smart grids and defense.

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by
ADTRAN Holdings, Inc. 
www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240624939927/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye